Chronic Hepatitis B
Conditions
Interventions
Treatment Group:Specific Cytotoxic T Lymphocytes (CTLs) Induced by Autologous Dendritic Cells(DCs) Transduced With Adeno-associated Virus(AAV) Carrying Different Hepatitis B Virus (HBV) Antigen Gene F
Sponsors
Chongqing Three Gorges Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female, 18 Years to 70 Years at the time of signing informed consent; 2. Genotype C hepatitis B patients, HBsAg and HBeAg positive for more than 6 months; 3. The load of hepatitis B virus DNA was lower than 5x10^2 IU/ml in subjects being treated with nucleos(t)ide analogue; 4. subjects volunteered to join, and signed the informed consent before treatment.
Exclusion criteria
Exclusion criteria: 1. Co-infected with other hepatitis virus (including HCV, HAV, HDV, HEV) or HIV 2. Decompensated liver disease 3. autoimmune diseases 4. ALT or AST> 10 ULN, or total bilirubin > 2 mg/dL 5. Hepatocellular carcinoma (HCC) or other malignant tumors; 6. T cell lymphoma; 7. Severe infection within past 2 weeks; 8. Allergy to biological agents such as granulocyte colony-stimulating factor; 9. Undergoing systemic radiotherapychemotherapy or immunosuppressive agents; 10. Blood routine was significantly abnormal: the total number of white blood cells was lower than 3.5x10^9, and the hemoglobin was less than 110g/L; 11. Subjects or his/her family members with a history of seizures or psychiatric disability 12. Clinically significant renal, respiratory, cerebral, cardiovascular or endocrine disease such as?severe thyroid dysfunction 13. Pregnancy and lactation 14. Voluntarily withdrew from the study; 15. Drug addicts or alcoholism 16. One or more additional known primary or secondary causes of liver disease, e.g., alcohol-induced hepatitisdrug-induced hepatitisautoimmune hepatitishemochromatosisalpha-1 antitrypsin deficiency, Wilson's Disease, Gilbert's syndrome, Dubin-Johnson syndrome and other reasons considered to be exclused by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;HBeAg; | — |
Countries
China
Contacts
Public ContactWu Guicheng
Chongqing Three Gorges Central Hospital
Outcome results
None listed